Versor Investments’s CorMedix CRMD Stock Holding History

Versor Investments’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-51,400	Closed	-$598K	–	168
2025 Q4	$598K	Buy	+51,400	New	+$568K	0.09%	270

Other funds holding CRMD

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Versor Investments's CRMD Position: Q1 2026 in Review

Versor Investments sold out of CorMedix (CRMD) in Q1 2026, closing a stake of 51,400 shares — an estimated $598K sold.

Versor Investments first reported a position in CRMD in Q4 2025 and held it in 1 quarter. The position peaked at $598K in Q4 2025. 188 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

Versor Investments reported no remaining CorMedix position as of Q1 2026 after selling out during the quarter.
Versor Investments sold 51,400 CorMedix shares in Q1 2026, an estimated $598K.
Versor Investments first reported a position in CorMedix in Q4 2025 and held it in 1 quarter.
Versor Investments's CorMedix position peaked at $598K in Q4 2025.
188 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Versor Investments's 13F filing for Q1 2026, filed 12 May 2026.